Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant – an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine.
Allergan plc , a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two...